Inmagene Biopharmaceuticals
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
122 15th St Unit 2685, Del Mar, Californ...Website
www.inmagenebio.comRevenue
$8.1 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Inmagene Biopharmaceuticals
Inmagene is a clinical-stage biotech company developing innovative and differentiated therapies for immunological and inflammatory diseasesExplore more
Inmagene Biopharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Inmagene Biopharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Inmagene Biopharmaceuticals launches new products
Check if Inmagene Biopharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Inmagene Biopharmaceuticals has new funding data
Inmagene Biopharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Inmagene Biopharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Inmagene Biopharmaceuticals
Click to see if Inmagene Biopharmaceuticals had a recent Job posting/layoffs
Earning: See what the market has to say on Inmagene Biopharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Inmagene Biopharmaceuticals
Find 3 more new buyers
Compare Similar Companies to Inmagene Biopharmaceuticals
Compare insights from companies similar to Inmagene Biopharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Inmagene Biopharmaceutica...
$8.1M
51-200
Private
$21M
2019
SG
Shailender GunnalaSenior Head of IT, Vice President, Ai & Facilities
$123.9M
51-200
Public
$547.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Company Profile Activity
Activity Insights
Inmagene Biopharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Inmagene Biopharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Inmagene Biopharmaceuticals.
Inmagene Biopharmaceuticals financials insights
Gather financial insights about Inmagene Biopharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series B
$21M
Inmagene Biopharmaceuticals Tech Stack
A closer look at the technologies used by Inmagene Biopharmaceuticals
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Event
Inmagene Biopharmaceuticals News & Media
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio (“Imagene”), of the combined company after the anticipated closing.Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals
BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” the “Company”) today announced that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”) recommend that stockholders vote FOR the issuance of shares in connection with the previously disclosed proposed merger with Inmagene Biopharmaceuticals (“Inmagene”) at Ikena’s upcoming Annual Meeting of Stockholders on July 15, 2025.Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene"), a clinical-stage biotechnology company dedicated to developing innovative and differentiated therapies for immunological and inflammatory diseases, today announced the successful dosing of the first patient in its global multicenter Phase 2b dose-finding study (ADAPTIVE Trial, NCT07037901) of IMG-007 in patients with moderate-to-severe atopic dermatitis (AD).
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Inmagene Biopharmaceuticals
Sign Up For FreeTo access detailed company insights
Inmagene is a clinical-stage biotech company developing innovative and differentiated therapies for immunological and inflammatory diseases... Read More
